PharmacoEconomics

The Dilemma of New Drugs: Are Costs Rising Faster than Effectiveness?
pp. 653-657(5)
Authors: Mason J.; Freemantle N.

Common Errors and Controversies in Pharmacoeconomic Analyses
pp. 659-666(8)
Authors: Byford S.; Palmer S.

The Economic Burden of Migraine to Society
pp. 667-676(10)
Author: Ferrari M.D.

Socioeconomics of a Global Leprosy Eradication Programme
pp. 677-686(10)
Authors: Naik S.S.; Ganapati R.

The Influence of Ill-Health Experience on the Valuation of Health
pp. 687-696(10)
Authors: Badia X.; Herdman M.; Kind P.

Modelling the Potential Economic Impact of Viral Load-Driven Triple Drug Combination Antiretroviral Therapy
pp. 697-705(9)
Authors: Anis A.H.; Hogg R.S.; Wang X-h.; Yip B.; Palepu A.; Montaner J.S.G.; O’Shaughnessy M.V.; Schechter M.T.

MSQ: Migraine-Specific Quality-of-Life Questionnaire: Further Investigation of the Factor Structure
pp. 707-717(11)
Authors: Jhingran P.; Davis S.M.; LaVange L.M.; Miller D.W.; Helms R.W.

The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany: Economic Evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study
pp. 719-730(12)
Authors: Schädlich P.K.; Brecht J.G.